F. Hoffmann-La Roche AG

Switzerland

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

1 November 2017 - 31 October 2018

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 November 2017 - 31 October 2018 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

AC	FC
127	51.94

Outputs by subject (FC)

Subject	AC	FC
Life Sciences	103	41
Cancer Cell	3	1.42
Cancer Research	2	0.54
Cell	3	1.12
Cell Metabolism	1	1
Cell Stem Cell	2	0.07
Developmental Cell	1	0.07
Genome Research	1	0.20
Journal of Biological Chemistry	9	3.27
Journal of Cell Biology	2	2
Journal of Clinical Investigation	2	0.17
Journal of Experimental Medicine	4	2.96
Journal of Neuroscience	3	1.55
Molecular Cell	3	2.04
Nature	5	3.59
Nature Cell Biology	1	0.04
Nature Chemical Biology	1	0.94
Nature Communications	21	4.48
Nature Genetics	2	0.04
Nature Immunology	5	1.51
Nature Medicine	3	1.07
Nature Methods	1	0.95
Nature Neuroscience	1	0.05
Neuron	1	0.88
PLOS Biology	1	0.05
Proceedings of the National Academy of Sciences of the United States of America	11	6.71
Science	2	0.06
Science Translational Medicine	5	1.64
The EMBO Journal	1	0.45
eLife	6	2.12
Chemistry	28	12.58
Physical Sciences	3	0.06

Highlight of the month

New antibiotic kills multidrug-resistant superbugs

By chemically optimizing an antibiotic naturally produced by soil bacteria, a Genentech-led team has made a molecule that can kill nasty drug-resistant superbugs.

Researchers at the Roche subsidiary started with arylomycin — a natural product that targets the signal peptidase enzyme found on the surface of bacteria but has only weak activity. They then extensively modified the molecule while keeping its core unchanged to produce G0775, a potent agent that works at doses 500 times lower than natural arylomycin to kill a broad spectrum of microbes — including notoriously hard-to-treat ‘Gram-negative’ bacteria.

The drug also protected mice from lethal infections, and bacteria showed a low potential for becoming resistant to it.

Because optimized arylomycins like G0775 work through a unique mechanism of action, the researchers argue that they represent “a much-needed new class” of antibiotics to combat the growing threat of multidrug-resistant pathogens.

Supported content